LTRN · Lantern Pharma Inc.
$2.56
-0.04 (-1.54%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the existence of substantial doubt regarding our ability to continue as a going concern in the absence of obtaining substantial additional funding”View the 10-Q filed May 15, 2026
Market Cap
$29.39M
Shares
11.30M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Panna Sharma | CEO | $1,090,634 |
| David Margrave | CFO | $752,886 |
| Kishor Bhatia | Chief Scientific Officer | $539,120 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Panna Sharma | CEO | $684,385 |
| David Margrave | CFO | $442,680 |
| Kishor Bhatia | Chief Scientific Officer | $283,237 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Panna Sharma | CEO | $1,053,818 |
| David Margrave | CFO | $394,359 |
| Kishor Bhatia | Chief Scientific Officer | $184,327 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Panna Sharma | CEO | $622,000 |
| David Margrave | CFO | $561,315 |
| Kishor Bhatia | Chief Scientific Officer | $282,140 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Panna Sharma | CEO | $1,594,166 |
| David Margrave | CFO | $1,160,962 |
| Kishor Bhatia | Chief Scientific Officer | $667,608 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Panna Sharma | CEO | $331,923 |
| David Margrave | CFO | $97,019 |
| Kishor Bhatia | Chief Scientific Officer | $36,873 |